|
KMID : 0939920080400010036
|
|
대한암학회지
2008 Volume.40 No. 1 p.36 ~ p.37
|
|
|
Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy
|
|
Kim Eui-Bae
Kim Seok-Jin
Roh Kyong-Ho
Kim Dae-Sik
Park Seh-Jong
Park Yong
|
|
|
Abstract
|
|
|
|
Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin’s lymphoma. However, its use has been implicated in HBV reactivation that’s related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/ HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOPchemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases. (Cancer Res Treat. 2008;40:36-38)
|
|
|
KEYWORD
|
|
|
Rituximab, Hepatitis B virus, Lymphoma
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|